Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB25FT1Z8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $6,849
Award facts
- Contract value 100% obligated
- $6,848.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $6,848.92 to DMS Pharmaceutical Group Inc. for 300 mg/2 mL Xolair auto-injector units. Xolair (omalizumab) is a monoclonal antibody therapeutic commonly used to treat moderate-to-severe allergic asthma and chronic idiopathic urticaria in military and federal healthcare settings. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 24, 2025, does not utilize a set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform the work at its principal place of business.
This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 through November 2026 under the SPE2DB program. The parent contract authorizes the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting military health facility needs worldwide. DMS Pharmaceutical Group has established itself as a critical pharmaceutical supplier within the federal supply chain, consistently delivering specialized medications, biologics, and medical consumables to Department of Defense healthcare facilities. The contractor's woman-owned small business status has enabled it to compete effectively in federal procurement markets while maintaining an extensive portfolio of branded and generic pharmaceutical products.
Quick answers
Who was awarded contract SPE2DB25FT1Z8?
SPE2DB25FT1Z8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 3, 2025.
How much is contract SPE2DB25FT1Z8 worth?
The government has obligated $6,849 on SPE2DB25FT1Z8.
Is contract SPE2DB25FT1Z8 an order under another contract?
Yes. SPE2DB25FT1Z8 is a delivery order under SPE2DB20D9371, an indefinite delivery contract.
Was contract SPE2DB25FT1Z8 competed?
The extent of competition for SPE2DB25FT1Z8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award